You are here: Industry Insights > CAR-T

News List

CAR-T race heads to Europe as Gilead, Novartis drugs score CHMP backing fiercepharma
July 02, 2018
Months after Novartis and Gilead Sciences won their CAR-T approvals in the U.S., the companies have scored CHMP recommendations for Kymriah and Yescarta in Europe.
FDA hits Ziopharm CAR-T trial with clinical hold fiercebiotech
June 25, 2018
Until recently, Ziopharm’s top priority was to get inducible adenoviral vector Ad-RTS-hIL-12 into a pivotal brain cancer trial.
IPO bonanza continues with $150M listing for CAR-T player Autolus fiercebiotech
June 25, 2018
Biotech IPOs continue to come thick and fast this week, with U.K. T-cell therapy specialist Autolus the latest to list with an impressive $150 million raise.
FDA places hold on Ziopharm CAR-T trial pharmafile
June 22, 2018
CAR-T is emerging as one of the most potentially exciting therapies in the industry, particularly as a beacon for the collective push towards personalised treatment, so it is unsurprising that many small biotechs are currently pursuing treatments within t
Could an old Amgen-developed RA drug make CAR-T treatments safer? fiercebiotech
June 11, 2018
The personalized CAR-T cells that are FDA-approved to treat blood cancers, Gilead’s Yescarta and Novartis’s Kymriah, can raise the risk of a side effect that has been challenging to prevent and treat: cytokine release syndrome (CRS).
LUYE pharma Joins US Firm to Develop Immuno-oncology Treatments biospectrumasia
May 30, 2018
The most advanced next generation dual-targeted CAR-T cell therapy drug derived from the Collaboration is in the IND enabling preclinical study stage
Novartis' CAR-T therapy gets second FDA approval pharmatimes
May 03, 2018
The FDA has approved Novartis' CAR-T therapy Kymriah (tisagenlecleucel) for intravenous infusion for its second indication - the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma ...
With hepatitis C in freefall, Gilead's bottoming out. The good news? It's bottoming out fiercebiotech
May 03, 2018
Gilead Sciences may have some exciting prospects on the horizon, but for now, its cash-cow hepatitis C business is a big drag. After hepatitis C sales cratered in the first quarter—falling even more than expected...
Watch out, Gilead—Novartis got the FDA nod it needs to steal your CAR-T market fiercepharma
May 03, 2018
Novartis won a second FDA approval last night for its CAR-T cancer treatment, Kymriah, potentially expanding the market for a product that has disappointed analysts .
Refuge Biotech scores $25M from Chinese backers for 'intelligent' CAR-T fiercebiotech
May 03, 2018
3SBio and Sequioa China led Refuge Biotechnologies' $25 million series B, which will advance the Bay Area biotech's dead Cas9-based cell therapies.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page